Cytokine-induced killer (CIK) cells show broad application prospects in adoptive immunotherapy for tumors. As a highly efficient, non-MHC-restricted killer cell population, CIK cells can effectively recognize and eliminate various tumor cells with minimal side effects. Obtaining a sufficient quantity of highly cytotoxic CIK cells relies heavily on a stable, reliable culture protocol and high-quality cytokines.

This article will detail the standard culture process for human CIK cells and emphasize how selecting high-purity, high-activity cytokines from UA BIOSCIENCE provides a solid foundation for the successful expansion and efficient activation of CIK cells.

CIK Cells: The "Elite Forces" in Tumor Immunotherapy

CIK cells are a heterogeneous population. Their main effector cells simultaneously express CD3 and CD56 molecules on the surface, thus combining the powerful anti-tumor activity of T lymphocytes with the non-MHC-restricted killing ability of NK cells. They can kill tumor cells through multiple mechanisms and have shown good therapeutic effects against various hematological malignancies and solid tumors.

Detailed CIK Cell Culture Protocol: The Three-Step Activation Method

A successful CIK cell culture cycle typically lasts 14 days, centered around the precise, timed addition of cytokines to regulate cell activation and proliferation.

Step 1: Collection and Preparation of Peripheral Blood Mononuclear Cells (PBMCs)

Collect patient PBMCs using apheresis.
Further purify PBMCs using density gradient centrifugation with lymphocyte separation medium.
Wash twice with serum-free culture medium to finally obtain PBMCs with purity >90%, serving as the "seed cells" for CIK culture.

Step 2: Stepwise Induction and Expansion of CIK Cells

Initiation Phase (Day 0): Resuspend PBMCs in serum-free culture medium and add the key initiation factor – 1000 U/mL recombinant human IFN-γ. Pre-stimulation with IFN-γ at this stage lays the crucial foundation for the subsequent efficient induction of CIK cells.
Activation & Proliferation Phase (Day 1):
- After 24 hours, add 50 ng/mL CD3 monoclonal antibody and 300 U/mL recombinant human IL-2. The CD3 antibody provides the key signal for T cell activation, while IL-2 is the core cytokine driving massive T cell proliferation.
- (Optional Enhancement Step): Concurrently add 100 U/mL recombinant human IL-1α. IL-1α acts as a co-stimulatory factor, potentially further promoting CIK cell activation and proliferation, and potentially improving the final cell yield and cytotoxic activity.
Maintenance & Expansion Phase (Day 1 - Day 14):
- Perform half-medium changes or flask expansions every 3 days, supplementing with 300 U/mL recombinant human IL-2 to maintain the cytokine concentration required for sustained cell proliferation.
- By day 14 of culture, a large quantity of highly cytotoxic CIK cells can be harvested.

Step 3: Quality Control and Characterization of CIK Cells

Harvested CIK cells must undergo strict quality control to ensure safety and efficacy:

Viability Assay: Trypan blue staining should show a viability rate >80%.
Phenotype Characterization: Flow cytometry analysis should show that the key CD3+CD56+ double-positive cell proportion is >20%. This population represents the most potent effector cells within the CIK cell product.
Functional Assay: Determine the in vitro cytotoxicity against tumor cell lines using methods like the lactate dehydrogenase (LDH) release assay.
Sterility and Endotoxin Testing: Ensure the cell product is free from bacterial, fungal, and mycoplasma contamination, with endotoxin levels <5 EU.

Why are UA BIOSCIENCE Cytokines the Cornerstone of Successful CIK Culture?

CIK cell culture is highly dependent on cytokine quality. The series of recombinant human cytokines provided by UA BIOSCIENCE, with their excellent performance, ensure the reproducibility of the CIK cell culture process and the high quality and efficiency of the final product.

The Core Value of UA Cytokines in the CIK Culture Protocol:

High Bioactivity Ensures Initiation Efficiency: The high specific activity of recombinant human IFN-γ is critical for the successful initiation of cells on Day 0, paving the way for subsequent induction. Low-activity IFN-γ leads to insufficient initiation, severely impacting later CIK cell expansion efficiency and phenotype development.
Drives Sustained Proliferation, Guaranteeing Cell Yield: Recombinant human IL-2 is the "power source" for CIK cells throughout the culture cycle. UA's IL-2 offers high purity and stability, continuously and effectively promoting CIK cell division and proliferation via autocrine and paracrine pathways, forming the fundamental guarantee for obtaining high cell numbers.
Synergistic Enhancement, Optimizing Cell Quality: Recombinant human IL-1α, as an optional enhancer, can create synergistic effects with IFN-γ and IL-2, further activating cells and potentially helping to increase the proportion of CD3+CD56+ effector cells in the final product and enhance overall killing function.
Stringent QC Standards Ensure Clinical Application Safety: For CIK cell cultures intended for clinical research, the purity, sterility, and low endotoxin levels of cytokines are paramount. UA BIOSCIENCE products undergo rigorous quality control, minimizing the risk of contamination by adventitious agents and providing strong support for preparing cell products that meet safety standards.

Recommended UA Core Cytokines for CIK Cell Culture:

UA040007E - IFN-γ Protein, Human: The "Starter Switch" for CIK cell induction.
UA040108 - IL-2 Protein, Human: The "Core Engine" for CIK cell proliferation.
UA040204 - IL-1α Protein, Human: The "Powerful Booster" for CIK cell activation.

Conclusion

A stable and efficient CIK cell culture system is the prerequisite for conducting related tumor immunotherapy research and application. Selecting high-quality cytokines is the most critical part of building this system. UA BIOSCIENCE, with its high-quality, high-activity cytokine products, provides reliable support throughout your journey from research to pre-clinical development.

Technical Articles